<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446328</url>
  </required_header>
  <id_info>
    <org_study_id>2010/3387</org_study_id>
    <secondary_id>11/01070</secondary_id>
    <secondary_id>2010-022307-22</secondary_id>
    <nct_id>NCT01446328</nct_id>
  </id_info>
  <brief_title>Bergen Psychosis Project 2 - The Best Intro Study</brief_title>
  <acronym>BP2</acronym>
  <official_title>Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Vest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and
      olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses
      and followed for 12 months. The study is independent of the pharmaceutical industry, and in
      accordance with a pragmatic design a clinically relevant sample will be included with as few
      exclusion criteria as possible. The patients will be assessed repeatedly with regards to
      symptoms, side effects, and cognitive functioning, as well as laboratory parameters. The
      study hypothesis is that clinically meaningful differences among the drugs will be disclosed
      in a pragmatic design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the Positive and Negative Syndrome Scale total score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Tablets, dose range 50-1200 mg/ day</description>
    <arm_group_label>Amisulpride</arm_group_label>
    <other_name>Solian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Tablets, dose range 5-30 mg/ day</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Tablets, dose range 2.5-20 mg/ day</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A:The observational cohort

          -  Patients 16 years old or older

          -  Active psychosis as determined by a score of 4 or more on one or more of the items
             Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or
             Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).

          -  Or ICD-10 diagnosis corresponding to psychotic disorders or other mental disorders
             with psychotic features (F10-F19: .5 (psychotic disorder); F20-F29, F30.2, F31.2,
             F31.5, F32.3, F33.3). From which eligible patients are recruited to the B:The
             pragmatic, randomized, controlled trial (The Best Intro Study)

          -  Patients 18 years and older

          -  Schizophrenia spectrum and delusional disorder

          -  Symptoms of psychosis as determined by a score of 4 or more on one or more of the
             items Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/ persecution, or
             Unusual thought content in the Positive and Negative Syndrome Scale (PANSS).

        Exclusion Criteria:

          -  Inability to understand spoken Norwegian.

          -  Patients with organic psychosis due to limbic encephalitis detected by antibodies in
             serum obtains at inclusion (such as NMDAR, VGKC and paraneoplastic antibodies
             performed at the Neuroimmunology Laboratory, Department of Neurology, Haukeland
             University Hospital) Pregnant or breast feeding women.

          -  Aripiprazole: Hypersensitivity to the active substance or to any of the excipients

          -  Amisulpride: Hypersensitivity to the active ingredient or to other ingredients of the
             medicinal product; concomitant prolactin-dependent tumours e.g. pituitary gland
             prolactinomas and breast cancer; phaeochromocytoma; lactation, combination with the
             following medications which could induce torsade de pointes: Class Ia antiarrhythmic
             agents such as quinidine, disopyramide, procainamide. Class III antiarrhythmic agents
             such as amiodarone, sotalol. Other medications such as bepridil, cisapride,
             sultopride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine,
             pentamidine, sparfloxacin. Combinations with levodopa.

          -  Olanzapine: Hypersensitivity to the active substance or to any of the excipients.
             Patients with known risk of narrow-angle glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Johnsen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universit√§t Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5223</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipsychotic Drugs</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Treatment Effectiveness</keyword>
  <keyword>Translational Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

